INTRODUCTION
MR, typhoid conjugate vaccine
In 2017, the World Health Organization prequalified the first typhoid conjugate vaccine (Typbar TCV) and deems anti-Vi IgG an appropriate measure of vaccine immunogenicity [We evaluated anti-Vi IgA antibodies 28 days after vaccination, and anti-Vi IgG and IgA antibodies 30–35 months post-vaccination in participants from a clinical trial where TCV was coadministered with routine MR vaccine, with and without MCV-A, at the 15-month vaccination visit [